Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables - Other: 2015-2023

Historic Receivables - Other for ImmunityBio (IBRX) over the last 9 years, with Dec 2023 value amounting to $2.0 million.

  • ImmunityBio's Receivables - Other rose 130.86% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 130.86%. This contributed to the annual value of $2.0 million for FY2023, which is 6.83% up from last year.
  • As of FY2023, ImmunityBio's Receivables - Other stood at $2.0 million, which was up 6.83% from $1.9 million recorded in FY2022.
  • ImmunityBio's 5-year Receivables - Other high stood at $2.0 million for FY2023, and its period low was $222,000 during FY2019.
  • In the last 3 years, ImmunityBio's Receivables - Other had a median value of $1.9 million in 2022 and averaged $1.7 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 97.96% in 2019, then spiked by 802.25% in 2020.
  • Over the past 5 years, ImmunityBio's Receivables - Other (Yearly) stood at $222,000 in 2019, then soared by 802.25% to $2.0 million in 2020, then crashed by 33.45% to $1.3 million in 2021, then surged by 41.79% to $1.9 million in 2022, then increased by 6.83% to $2.0 million in 2023.